Does Carvedilol Interact with Ubrogepant?
CDI records a moderate classification for Carvedilol and Ubrogepant. The stored summary is: BCRP and/or P-gp inhibitor that may increase ubrogepant exposure. Dose adjustment recommended. The mechanism involves bcrp and/or p-gp inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Carvedilol Class
- alpha-Adrenergic Blocker
- Ubrogepant Class
- Calcitonin Gene-related Peptide Receptor Antagonist
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
BCRP and/or P-gp inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Carvedilol and your doctor is considering prescribing Ubrogepant (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider